{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T12:28:31Z","timestamp":1763814511933,"version":"3.45.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,22]]},"DOI":"10.7759\/cureus.97493","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T12:23:41Z","timestamp":1763814221000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Pembrolizumab as Conversion Therapy in Deficient Mismatch Repair\/Microsatellite Instability-High Metastatic Liver Colorectal Cancer Associated With Lynch Syndrome: A Case-Based Analysis"],"prefix":"10.7759","author":[{"given":"Andr\u00e9s de Jes\u00fas","family":"Le\u00f3n-Sand\u00ed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimena","family":"Ag\u00fcero-Moraga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Ramos-Esquivel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-97242-3_5","article-title":"Colorectal cancers and immunotherapy","volume":"129","author":"Teymouri F","year":"2025","unstructured":"Teymouri F, Brar G. Colorectal cancers and immunotherapy. Cancer Treat Res. 2025, 129:83-102. 10.1007\/978-3-031-97242-3_5","journal-title":"Cancer Treat Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115233","article-title":"Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact","volume":"217","author":"Venetis K","year":"2025","unstructured":"Venetis K, Frascarelli C, Bielo LB, et al.. Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact. Eur J Cancer. 2025, 217:115233. 10.1016\/j.ejca.2025.115233","journal-title":"Eur J Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.32604\/or.2025.063951","article-title":"Lynch syndrome and colorectal cancer: A review of current perspectives in molecular genetics and clinical strategies","volume":"33","author":"G\u00f3mez-Molina R","year":"2025","unstructured":"G\u00f3mez-Molina R, Mart\u00ednez R, Su\u00e1rez M, Pe\u00f1a-Cabia A, Calder\u00f3n MC, Mateo J. Lynch syndrome and colorectal cancer: A review of current perspectives in molecular genetics and clinical strategies. Oncol Res. 2025, 33:1531-45. 10.32604\/or.2025.063951","journal-title":"Oncol Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.109821","article-title":"Cancer immunotherapy: Pros, cons and beyond","volume":"124","author":"Tan S","year":"2020","unstructured":"Tan S, Li D, Zhu X. Cancer immunotherapy: Pros, cons and beyond. Biomed Pharmacother. 2020, 124:109821. 10.1016\/j.biopha.2020.109821","journal-title":"Biomed Pharmacother"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes A","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, et al.. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023, 34:10-32. 10.1016\/j.annonc.2022.10.003","journal-title":"Ann Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1","article-title":"Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC)","volume":"43","author":"Sinicrope FA","year":"2025","unstructured":"Sinicrope FA, Ou FS, Arnold D, et al.. Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC). J Clin Oncol. 2025, 43:10.1200\/JCO.2025.43.17_suppl.LBA1","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9 T","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, et al.. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020, 383:2207-18. 10.1056\/NEJMoa2017699","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE- 177): Final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz LA Jr","year":"2022","unstructured":"Diaz LA Jr, Shiu KK, Kim TW, et al.. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE- 177): Final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022, 23:659-70. 10.1016\/s1470-2045(22)00197-8","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): A randomised, open-label, phase 3 trial","volume":"405","author":"Andr\u00e9 T","year":"2025","unstructured":"Andr\u00e9 T, Elez E, Lenz HJ, et al.. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): A randomised, open-label, phase 3 trial. Lancet. 2025, 405:383-95. 10.1016\/S0140-6736(24)02848-4","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek A","year":"2022","unstructured":"Cercek A, Lumish M, Sinopoli J, et al.. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022, 386:2363-76. 10.1056\/NEJMoa2201445","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer","volume":"390","author":"Chalabi M","year":"2024","unstructured":"Chalabi M, Verschoor YL, Tan PB, et al.. Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. N Engl J Med. 2024, 390:1949-58. 10.1056\/NEJMoa2400634","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03250-w","article-title":"Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: A phase 2 trial","volume":"30","author":"de Gooyer PG","year":"2024","unstructured":"de Gooyer PG, Verschoor YL, van den Dungen LD, et al.. Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: A phase 2 trial. Nat Med. 2024, 30:3284-90. 10.1038\/s41591-024-03250-w","journal-title":"Nat Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/gidisord5040046","article-title":"Colorectal cancer liver metastasis\u2014state-of-the-art and future perspectives","volume":"5","author":"Ruivo A","year":"2023","unstructured":"Ruivo A, Oliveira RC, Silva-Vaz P, Tralh\u00e3o JG. Colorectal cancer liver metastasis\u2014state-of-the-art and future perspectives. Gastrointest Disord. 2023, 5:580-608. 10.3390\/gidisord5040046","journal-title":"Gastrointest Disord"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000138076.72547.b1","article-title":"Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET)","volume":"240","author":"Fernandez FG","year":"2004","unstructured":"Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004, 240:438-47; discussion 447-50. 10.1097\/01.sla.0000138076.72547.b1","journal-title":"Ann Surg"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60455-9","article-title":"Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial","volume":"371","author":"Nordlinger B","year":"2008","unstructured":"Nordlinger B, Sorbye H, Glimelius B, et al.. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet. 2008, 371:1007-16. 10.1016\/S0140-6736(08)60455-9","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12662-3","article-title":"Safety of first-line systemic therapy in patients with metastatic colorectal cancer: A network meta-analysis of randomized controlled trials","volume":"24","author":"Zhan Y","year":"2024","unstructured":"Zhan Y, Cheng X, Mei P, Tan S, Feng W, Jiang H. Safety of first-line systemic therapy in patients with metastatic colorectal cancer: A network meta-analysis of randomized controlled trials. BMC Cancer. 2024, 24:893. 10.1186\/s12885-024-12662-3","journal-title":"BMC Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu580","article-title":"Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: The OLIVIA multinational randomised phase II trial","volume":"26","author":"Gruenberger T","year":"2015","unstructured":"Gruenberger T, Bridgewater J, Chau I, et al.. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: The OLIVIA multinational randomised phase II trial. Ann Oncol. 2015, 26:702-8. 10.1093\/annonc\/mdu580","journal-title":"Ann Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00253","article-title":"Outcomes of chemotherapy for microsatellite instable-high metastatic colorectal cancers","volume":"2","author":"Shulman K","year":"2018","unstructured":"Shulman K, Barnett-Griness O, Friedman V, Greenson JK, Gruber SB, Lejbkowicz F, Rennert G. Outcomes of chemotherapy for microsatellite instable-high metastatic colorectal cancers. JCO Precis Oncol. 2018, 2:10.1200\/PO.17.00253","journal-title":"JCO Precis Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le DT","year":"2020","unstructured":"Le DT, Kim TW, Van Cutsem E, et al.. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020, 38:11-9. 10.1200\/JCO.19.02107","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4019","article-title":"10-year follow up of a phase 2 clinical trial of pembrolizumab (pembro) in microsatellite instability-high (MSI-H)\/mismatch repair deficient (dMMR) advanced solid tumors","volume":"43","author":"Bever KM","year":"2025","unstructured":"Bever KM, Durham JN, Qi H, et al.. 10-year follow up of a phase 2 clinical trial of pembrolizumab (pembro) in microsatellite instability-high (MSI-H)\/mismatch repair deficient (dMMR) advanced solid tumors. J Clin Oncol. 2025, 43:10.1200\/JCO.2025.43.16_suppl.4019","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/435311-efficacy-of-pembrolizumab-as-conversion-therapy-in-deficient-mismatch-repairmicrosatellite-instability-high-metastatic-liver-colorectal-cancer-associated-with-lynch-syndrome-a-case-based-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T12:23:42Z","timestamp":1763814222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/435311-efficacy-of-pembrolizumab-as-conversion-therapy-in-deficient-mismatch-repairmicrosatellite-instability-high-metastatic-liver-colorectal-cancer-associated-with-lynch-syndrome-a-case-based-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.97493","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,22]]}}}